The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review [PDF]
Saudi Pharmaceutical Journal, 2022 Background: Throughout the time of the global pandemic of SARS-CoV-2 virus, there has been a compelling necessity for the development of effective antiviral agents and prophylactic vaccines to limit the virus spread, disease burden, hospitalization, and ...
Lina Kamal +4 more
doaj +2 more sources
Drug repurposing screens identify chemical entities for the development of COVID-19 interventions [PDF]
Nature Communications, 2021 Here, the authors perform repurposing screens of the ReFRAME drug library in two cell lines and identify inhibitors of SARS-CoV-2 infection. Antiviral activity of prodrug MK-4482 is confirmed in hamsters.
Malina A. Bakowski +31 more
doaj +2 more sources
Clinical and Translational Science, 2022 Molnupiravir (MK‐4482) is an oral prodrug of the antiviral ribonucleoside analog, N‐hydroxycytidine (NHC), which has activity against RNA viruses, including severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2).
Keisuke Nakamura +14 more
doaj +2 more sources
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19 [PDF]
Molecules, 2021 The COVID-19 pandemic needs no introduction at present. Only a few treatments are available for this disease, including remdesivir and favipiravir. Accordingly, the pharmaceutical industry is striving to develop new treatments for COVID-19. Molnupiravir,
Mohd. Imran +13 more
doaj +2 more sources
Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 Treatment [PDF]
Bioinformatics and Biology Insights, 2022 As SARS-CoV-2 continues to evolve and spread with the emergence of new variants, interest in small molecules with broad-spectrum antiviral activity has grown.
John Maringa Githaka
doaj +2 more sources
Embracing Uncertainties Over the Evidence of New Oral Antivirals for COVID-19: Challenges in Pharmacoepidemiologic Research. [PDF]
J Clin Pharmacol, 2023 The Journal of Clinical Pharmacology, Volume 63, Issue 5, Page 521-525, May 2023.
Ferreira da Silva R +4 more
europepmc +2 more sources
A Concise Route to MK-4482 (EIDD-2801) [PDF]
Nucleosides, Nucleotides & Nucleic Acids, 2020 A two-step route to MK-4482 (EIDD-2801, 1 ) was developed consisting of an esterification and hydroxamination of cytidine. The reactions can be conducted in either order with overall yields of 67% (first step—esterification) and 37% (first step—hydroxamination). Selective esterification of the
Natarajan Vasudevan +10 more
openaire +3 more sources
Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open-Label, Fixed Sequence, Phase 1 Study. [PDF]
Clin Transl SciABSTRACT Molnupiravir is an orally administered prodrug of β‐D‐N4‐hydroxycytidine (NHC) that is conditionally approved in China for the treatment of mild to moderate COVID‐19 in nonhospitalized adults at high risk of disease progression. Molnupiravir is rapidly absorbed and hydrolyzed to deliver NHC into systemic circulation.
Zhu J +10 more
europepmc +2 more sources
A Concise Route to MK-4482 (EIDD-2801) from Cytidine: Part 2 [PDF]
Synlett, 2020 A new route to MK-4482 ( 1 ) was developed. The route replaces uridine with the more available and less expensive cytidine. Low cost, simple reagents are used for the chemical transformations and the yield is improved from 17% to 44%.
Snead, David R. +5 more
openaire +3 more sources
Infectious Diseases and Therapy, 2023 Introduction The randomized, placebo-controlled, double-blind MOVe-OUT trial demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for outpatient treatment of mild-to-moderate COVID-19, significantly reducing the risk of ...
Julie M. Strizki +9 more
doaj +1 more source